News

Novozymes buys Iogen’s enzymes
Enlarge image

BusinessDenmark

Novozymes buys Iogen’s enzymes

01.02.2013 - With a €50m acquisition Novozymes puts a foot in the pulp & paper, textile, grain-processing and animal feed industries

On January 31st, the Danish enzyme specialist annouced that it will acquire the industrial enzyme business of Canadian cellulosic ethanol specialist Iogen Corporation for €50m. Earn-out payments of up to additional €10m could add to the sum. With the deal Novozymes bags the entire product portfolio of Iogen Bio-Products, including products in development, production sites and IP.

Iogen Bio-Products produces fibre modifying enzymes, such as pulp bleaching enzymes for the pulp and paper branch, fibre processing biocatalysts for textile sector, cellulases and hemicellulases fort he grain-processing and enzymes fort he animal feed industries. Closing of the take-over is expected in February 2013. With the deal Novozymes strenghtens its market position in industrial biotech which complements its already strong position in the cellulosic bioethanol segment that is expanded with aquisitions and collaborations.

© eurobiotechnews.eu/tg 

http://www.european-biotechnology-news.com/news/news/2013-01/novozymes-buys-iogens-enzymes.html

GenericsEUUKHungaryGermanyItalyGreeceAustriaLuxembourgFranceSpain

26.02.2015 It is the first biosimilar monoclonal antibody in many European markets: Mundipharma and Hospira are launching Celltrion’s Remicade generic.

M&AUK

23.02.2015 British drug developer Heptares has been acquired by Japanese biopharma play Sosei for US$400m (€352m).

bioethanolGermanyUKBelgiumFrance

19.02.2015 The price of oil has been sliding for months, and the European bioethanol market is taking it hard. CropEnergies AG has now stopped production at its British unit Ensus UK.

BusinessFranceGermany

17.02.2015 After Christopher Viehbacher’s unceremonious ousting last year, Sanofi has been on the look out for a new CEO. Now, sources say Bayer’s Olivier Brandicourt is set to fill the position.

BusinessUKSwitzerland

12.02.2015 Glaxosmithkline is intent on bolstering its vaccine portfolio further and has bought all shares of Swiss development partner Glycovaxyn.

InvestmentsUKEU

10.02.2015 Interest in biotechnology is on the rise among British investors. Not just one, but two major financiers are planning investment funds in the field.

IVFUKEU

04.02.2015 In a historic move, the UK is set to become the first country to allow the creation of babies with the genetic material of three people – a mother, a father and a female mitochondrial donor.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • WILEX3.43 EUR13.20%
  • EVOLVA1.55 CHF4.73%
  • BASILEA122.20 CHF4.44%

FLOP

  • MOLOGEN5.38 EUR-4.78%
  • BIOFRONTERA1.84 EUR-3.16%
  • MORPHOSYS74.76 EUR-3.01%

TOP

  • WILEX3.43 EUR72.4%
  • FORMYCON16.70 EUR20.1%
  • BASILEA122.20 CHF17.0%

FLOP

  • BIOFRONTERA1.84 EUR-8.9%
  • SANTHERA94.55 CHF-8.2%
  • ADDEX3.20 CHF-7.0%

TOP

  • SANTHERA94.55 CHF2336.9%
  • WILEX3.43 EUR481.4%
  • FORMYCON16.70 EUR106.7%

FLOP

  • CYTOS0.34 CHF-88.7%
  • MOLOGEN5.38 EUR-55.7%
  • BIOFRONTERA1.84 EUR-53.3%

No liability assumed, Date: 26.02.2015